Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.51 |
| ▸ | RARA | P10276 | 8/20 | 0.51 |
| ▸ | RARG | P13631 | 8/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683976 | 1.00 | RARB (0.51) | RARBRARARARGRXRAABCG2 | |
| SCHEMBL8168025 | 0.91 | TDP1 (0.42) | RARBRARARARGABCG2TDP1 | |
| SCHEMBL7930726 | 0.89 | RARB (0.47) | RARBRARARARGRXRATDP1 | |
| SCHEMBL7922680 | 0.86 | RARB (0.51) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL7929287 | 0.85 | RARB (0.50) | RARBRARARARGRXRAALDH1A1 | |
| SCHEMBL1683959 | 0.83 | RARB (0.48) | RARBRARARARGRXRALTB4R | |
| SCHEMBL1683960 | 0.83 | RARB (0.48) | RARBRARARARGRXRALTB4R | |
| SCHEMBL8169474 | 0.80 | EGFR (0.43) | RARBRARARARGTDP1L3MBTL1 | |
| SCHEMBL1683992 | 0.80 | RARB (0.53) | RARBRARARARGRXRATDP1 | |
| SCHEMBL1683993 | 0.80 | RARB (0.53) | RARBRARARARGRXRATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| EP-1255543-B1 | USE OF RETINOID-TYPE COMPOUNDS AS ANTIBACTERIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | GALDERMA RES & DEV (FR) | 2010-09-01 | — | — | EP | claimed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | claimed |
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | SPECIAL PRODUCTS LINE S P A (IT) | 2026-02-05 | — | — | US | disclosed |
| US-20220281835-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | SPECIAL PRODUCTS LINE S P A (IT) | 2022-09-08 | — | — | US | disclosed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-1711210-B1 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2013-12-11 | — | — | EP | disclosed |
| EP-2392677-A2 | Combined use of prame inhibitors and hdac inhibitors | TopoTarget UK Limited (GB) | 2011-12-07 | — | — | EP | disclosed |
| US-7928081-B2 | biodrugs contains siRNA or vector encoding siRNA, including a retinoid as antitumor agents, anticarcinogenic agents | Bernards, Rene (NL) | 2011-04-19 | — | — | US | disclosed |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | BERNARDS RENE | 2008-05-22 | — | — | US | disclosed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035353-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | TLR7, GANC, ARG1 | RARB 2413/4885RARA 2620/4885RARG 2152/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARB 987/4885RARA 1211/4885RARG 744/4885 |
| US-20220281835-A1 | PHENOL DERIVATIVES FOR USE AS ANTIMICROBIAL, ANTIBACTERIAL, BACTERICIDE | UROD, PPARD, PGLS | RARB 1666/4885RARA 1672/4885RARG 2311/4885 |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | HDAC5, HDAC8, HDAC11 | RARB 14/4885RARA 29/4885RARG 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.